Related references
Note: Only part of the references are listed.Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug- Resistant HIV-1 Infection
Mario V. Beccari et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Recent progress in broadly neutralizing antibodies to HIV (vol 19, pg 1179, 2018)
Devin Sok et al.
NATURE IMMUNOLOGY (2019)
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody
Christoph H. Fellinger et al.
JOURNAL OF VIROLOGY (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
Kush Dhody et al.
HIV CLINICAL TRIALS (2018)
Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry
Salar N. Khan et al.
JOURNAL OF VIROLOGY (2018)
A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin
David Wensel et al.
JOURNAL OF VIROLOGY (2018)
eCD4-Ig Variants That More Potently Neutralize HIV-1
Ina Fetzer et al.
JOURNAL OF VIROLOGY (2018)
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and Spain
Deanna Kerrigan et al.
PLOS ONE (2018)
Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
James J. Steinhardt et al.
NATURE COMMUNICATIONS (2018)
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
Kshitij Wagh et al.
PLOS PATHOGENS (2018)
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
Yotam Bar-On et al.
NATURE MEDICINE (2018)
Engineering multi-specific antibodies against HIV-1
Neal N. Padte et al.
RETROVIROLOGY (2018)
Recent progress in broadly neutralizing antibodies to HIV
Devin Sok et al.
NATURE IMMUNOLOGY (2018)
Two-drug regimens for treatment of naive HIV-I infection and as maintenance therapy
Katya C. Corado et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL
Benoit Manfroi et al.
CANCER RESEARCH (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity
David Wensel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41
Hyun A. Yi et al.
CURRENT HIV RESEARCH (2016)
Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
Sean G. Kelly et al.
DRUGS (2016)
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies
Ruijiang Song et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Adnectin-Targeted Inhibitors: Rationale and Results
Esha Sachdev et al.
CURRENT ONCOLOGY REPORTS (2015)
Different Infectivity of HIV-1 Strains Is Linked to Number of Envelope Trimers Required for Entry
Oliver F. Brandenberg et al.
PLOS PATHOGENS (2015)
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure
Marcelo T. Augusto et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico
Gloria Huerta-García et al.
AIDS Research and Therapy (2014)
In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
Zhufang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity
Ruijiang Song et al.
NATURE BIOTECHNOLOGY (2013)
Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment Efficacy
Kieran Seay et al.
PLOS ONE (2013)
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1
Craig S. Pace et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
Fei Yu et al.
VIRUSES-BASEL (2013)
In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068
Beata Nowicka-Sans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2011)
Adnectins: engineered target-binding protein therapeutics
D. Lipovsek
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Jiunn H. Lin
CURRENT DRUG METABOLISM (2009)
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
Paolo Ingallinella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
John J. Dwyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions
P Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
E Chertova et al.
JOURNAL OF VIROLOGY (2002)
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1
C Spenlehauer et al.
VIROLOGY (2001)
Protein design of an HIV-1 entry inhibitor
MJ Root et al.
SCIENCE (2001)
Share Paper
